
Aptargroup (ATR) Stock Forecast & Price Target
Aptargroup (ATR) Analyst Ratings
Bulls say
AptarGroup's AMS Solutions segment has exhibited substantial growth since its acquisition, achieving a compound annual growth rate (CAGR) of approximately 10% and representing about 11% of Pharma's revenue and 5% of the company's total revenue for FY24. The company's Injectables business is also experiencing notable growth, with a 9% CAGR driven by the shift towards biologics and increased demand for GLP-1 drugs, which supports margin expansion. This strategic positioning in high-value products and their capacity to meet rising demand positions AptarGroup favorably for continued financial advancement.
Bears say
AptarGroup faces several challenges that contribute to a negative outlook on its stock, primarily related to its transitional strategy toward becoming a majority Pharma-focused company, which may hinder its anticipated growth and margin expansion. The company is also exposed to significant currency and country risks due to its global operations in North America, Asia, and Europe, alongside vulnerabilities associated with economic cycles that can affect industry demand. Additionally, ongoing trade tensions, potential regulatory inspection failures, and difficulties in maintaining the integrity of its intellectual property could further impair revenue generation and competitive positioning.
This aggregate rating is based on analysts' research of Aptargroup and is not a guaranteed prediction by Public.com or investment advice.
Aptargroup (ATR) Analyst Forecast & Price Prediction
Start investing in Aptargroup (ATR)
Order type
Buy in
Order amount
Est. shares
0 shares